Linda T. Vahdat, MD, from the Weill Cornell Medical College, discusses the combination of eribulin mesylate and trastuzumab as a first-line therapy for HER2-positive metastatic breast cancer.
Linda T. Vahdat, MD
Advertisement
Articles by Linda T. Vahdat, MD
Dr. Linda Vahdat, from New York-Presbyterian Hospital, Discusses the Side Effects of Halaven
Dr. Linda Vahdat, from the New York-Presbyterian Hospital, Compares Halaven and Ixempra Neuropathy
Advertisement
Latest Updated Articles
Dr. Vahdat Compares Halaven and Ixempra NeuropathyDecember 22nd 2011
Dr. Vahdat Discusses the Side Effects of HalavenJanuary 18th 2012
Dr. Vahdat on Frontline Eribulin Plus Trastuzumab in MBCFebruary 26th 2013
Advertisement
Advertisement
Trending on OncLive
1
HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA
2
Selinexor Plus Ruxolitinib Yields Superior Spleen Responses, OS Signal in JAK Inhibitor–Naïve Myelofibrosis
3
TALAPRO-3 Shows Talazoparib Plus Enzalutamide Improves rPFS in HRR-Altered mCSPC
4
Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg
5